VIVS

VivoSim Labs Inc

Sep 16 • 04:00PM ET

3.84

-0.94 -19.67 %

Healthcare • Biotechnology • USA • NASD

Peers: MDXG FATE VCEL BLUE CYRX CRSP EDIT NTLA ALLO SGMO

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	1.07%	Shs Outstand	2.60M	Perf Week	28.86%
Market Cap	9.99M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.57M	Perf Month	116.95%
Enterprise Value	1.76M	PEG	-	EPS next Q	-	Inst Own	4.95%	Short Float	1.48%	Perf Quarter	149.45%
Income	-1.99M	P/S	71.33	EPS this Y	-	Inst Trans	83.11%	Short Ratio	0.12	Perf Half Y	-24.81%
Sales	0.14M	P/B	1.05	EPS next Y	-	ROA	-18.53%	Short Interest	0.04M	Perf YTD	-30.42%
Book/sh	3.67	P/C	1.10	EPS next 5Y	-	ROE	-24.53%	52W High	21.96 -82.51%	Perf Year	-39.85%
Cash/sh	3.48	P/FCF	-	EPS past 3/5Y	52.42% 45.28%	ROIC	-20.20%	52W Low	1.41 172.34%	Perf 3Y	-87.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-54.21% -42.01%	Gross Margin	-83.80%	Volatility	23.41% 18.79%	Perf 5Y	-95.49%
Dividend TTM	-	EV/Sales	12.54	EPS Y/Y TTM	90.87%	Oper. Margin	-8552.82%	ATR (14)	0.50	Perf 10Y	-99.42%
Dividend Ex-Date	-	Quick Ratio	4.52	Sales Y/Y TTM	94.52%	Profit Margin	-1399.30%	RSI (14)	65.37	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.52	EPS Q/Q	58.51%	SMA20	46.31%	Beta	1.19	Target Price	64.80
Payout	-	Debt/Eq	0.09	Sales Q/Q	-5.13%	SMA50	74.77%	Rel Volume	1.70	Prev Close	4.78
Employees	13	LT Debt/Eq	0.03	Earnings	-	SMA200	19.75%	Avg Volume	308.89K	Price	3.84
IPO	Feb 14, 2012	Option/Short	No / Yes	EPS/Sales Surpr.	46.15% -26.83%	Trades		Volume	526,300	Change	-19.67%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-18	Initiated	H.C. Wainwright	Buy	$2.50
Nov-10-17	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-25-17	Initiated	Raymond James	Outperform
Aug-11-15	Downgrade	Cantor Fitzgerald	Buy → Hold
Jun-29-15	Initiated	Piper Jaffray	Overweight	$5
Jun-29-15	Initiated	Jefferies	Buy	$5

Sep-02-25 05:40AM	NIO, XPeng, Li Auto Log Strong August Deliveries Highlighting China's EV Momentum (Benzinga)
Aug-14-25 08:05AM	VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer (GlobeNewswire)
Aug-12-25 04:44PM	VivoSim: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +6.05%
May-13-25 08:05AM	VivoSim's NAMKind Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference (GlobeNewswire)
May-07-25 08:05AM	VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference (GlobeNewswire)
08:05AM	Loading…
Apr-24-25 08:05AM	VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market (GlobeNewswire) -8.33%
Apr-23-25 08:05AM	VivoSim to Carry Forward Organovo 3D Bioprinting (GlobeNewswire)
Apr-02-25 08:05AM	Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements (GlobeNewswire)
Mar-27-25 08:05AM	Organovo Provides Business Update (GlobeNewswire) -13.50%
Mar-25-25 11:25AM	Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company (GlobeNewswire) -5.02%
Mar-19-25 08:05AM	Organovo Announces Reverse Stock Split (GlobeNewswire) -32.61%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-06-25 08:05AM	Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises (GlobeNewswire)
Feb-25-25 08:05AM	Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company (GlobeNewswire) +244.17%
Feb-19-25 09:17AM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
08:05AM	Loading…
Jan-06-25 08:05AM	Organovo Announces Appointment of Norman Staskey as Chief Financial Officer (GlobeNewswire) +7.15%
Nov-20-24 08:05AM	Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting (GlobeNewswire)
Nov-13-24 08:06AM	Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-08-24 04:15PM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.60%
Jul-16-24 08:05AM	Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis (GlobeNewswire) -8.55%
Jun-03-24 11:52AM	ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace) +5.78%
May-21-24 08:05AM	Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease (GlobeNewswire)
May-14-24 11:00AM	Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024) (GlobeNewswire)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
May-08-24 08:00PM	Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering (GlobeNewswire) +5.49%
Apr-15-24 08:13AM	Organovo's fatty liver disease drug meets main goal in mid-stage study (Reuters) +33.65%
08:05AM	Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo (GlobeNewswire)
Mar-28-24 08:32PM	Top 15 3D Printing Companies in the US (Insider Monkey)
Feb-08-24 05:52PM	Organovo: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -10.00%
Jan-25-24 08:05AM	Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress (GlobeNewswire)
08:05AM	Loading…
Jan-09-24 08:05AM	Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress (GlobeNewswire)
Dec-06-23 08:05AM	Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results (GlobeNewswire) -6.04%
Nov-13-23 08:05AM	CORRECTION Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) +5.93%
Nov-10-23 05:08AM	Organovo: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -7.53%
Nov-08-23 08:05AM	Organovo Highlights FXR314 Combination Therapy Potential and Plan (GlobeNewswire) -5.18%
Oct-10-23 07:18AM	ONVO: A Company With Great Technology to Impact Health Care (Zacks)
Sep-08-23 12:46PM	Organovo to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 07:36PM	Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com) -13.16%
Aug-23-23 08:05AM	Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data (GlobeNewswire) +5.43%
Jul-12-23 03:01AM	Net Asset Value(s) (Business Wire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey)
Mar-21-23 08:05AM	Organovo Announces FXR Program (GlobeNewswire)
Feb-10-23 05:12AM	Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely? (Simply Wall St.) -17.86%
Nov-15-22 08:05AM	Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohns Disease Drug Candidates (GlobeNewswire)
Sep-06-22 08:20AM	Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +13.42%
08:05AM	Organovo Announces Postponement of Annual Meeting of Stockholders (GlobeNewswire)
Jul-08-22 08:05AM	We're Not Very Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Rate (Simply Wall St.) +29.17%
May-17-22 08:05AM	Organovo Achieves 3D Tissue Model for Crohns Disease (GlobeNewswire) +5.86%
Mar-03-22 10:13PM	Why Organovo Holdings, Inc. Stock Soared 49.7% This Week (Motley Fool) -11.34%
Mar-01-22 08:05AM	UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.90%
Feb-23-22 08:05AM	Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents (GlobeNewswire) +5.47%
Feb-18-22 04:00PM	Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:00PM	Organovo Welcomes New Sr. Vice President of Strategy and Business Development (GlobeNewswire)
Feb-12-22 02:09PM	10 3D Printing Companies to Watch in 2022 (Insider Monkey)
Feb-04-22 10:11AM	Cathie Wood Targets Illiquid Assets and Limits Exits in New Fund (Bloomberg)
Feb-02-22 12:00PM	Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents (GlobeNewswire)
Jan-21-22 11:37AM	15 Worst Stock Picks of Cathie Wood (Insider Monkey)
Jan-10-22 12:00PM	Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk (GlobeNewswire)
Dec-30-21 09:24AM	Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation (Simply Wall St.)
Nov-30-21 08:05AM	Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022 (GlobeNewswire)
Sep-17-21 04:10PM	Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum (GlobeNewswire) -7.57%
Jun-22-21 10:17AM	/C O R R E C T I O N from Source -- RBC Global Asset Management Inc./ (PR Newswire) +5.02%
Jun-15-21 11:38AM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey)
Mar-02-21 08:05AM	Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE) (GlobeNewswire)
Feb-07-21 09:19AM	15 Biggest 3D Companies in the World (Insider Monkey)
Sep-03-20 04:05PM	Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -5.75% -11.54%
Aug-17-20 08:05AM	Organovo Announces One-for-Twenty Reverse Stock Split (GlobeNewswire) -13.52%
Jun-10-20 03:43PM	Hedge Fund Sentiment Is Stagnant On Organovo Holdings Inc (ONVO) (Insider Monkey) -7.54%
Apr-08-20 10:32AM	Edited Transcript of ONVO earnings conference call or presentation 9-Nov-17 10:00pm GMT (Thomson Reuters StreetEvents) +13.63%
07:53AM	The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO (Benzinga)
Apr-07-20 04:12PM	Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics (Business Wire)
Apr-02-20 08:00AM	Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders Opposition to the Illogical Merger With Tarveda Therapeutics (GlobeNewswire) -13.19%
Mar-31-20 06:30PM	Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders (Business Wire) +43.36% -28.07%
03:25PM	Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt (GlobeNewswire)
Mar-28-20 02:27PM	How 3D-printing is playing a role in coronavirus testing (Yahoo Finance)
Mar-27-20 04:05PM	Organovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders (Business Wire)
Mar-23-20 03:30PM	Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders (GlobeNewswire) -10.80%
Mar-19-20 02:36PM	Organovo Founder Issues Letter to Stockholders Regarding Major Missteps and Misjudgment of the Companys Board of Directors (GlobeNewswire) +20.48%
Feb-26-20 08:30AM	Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders (Business Wire) -9.67%
Jan-21-20 07:00AM	The Case Against Tarveda: An Open Letter to Organovo Shareholders (Business Wire) -11.92%
Jan-07-20 08:00AM	An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting (Business Wire) +8.60%
Dec-17-19 07:03PM	Is Organovo Holdings Inc (ONVO) A Good Stock To Buy? (Insider Monkey) -13.11%
Dec-16-19 07:00AM	Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement (Business Wire) +24.12%
Nov-21-19 07:19AM	Will Organovo Continue to Surge Higher? (Zacks) -9.33%
Nov-18-19 09:18AM	Zacks.com featured highlights include: Avinger, Alexion Pharmaceuticals, CyberArk Software, Organovo and Qualys (Zacks)
Nov-15-19 07:06AM	What Bargain Hunting? Tap 5 Stocks With Rising P/E (Zacks) +13.75%
Nov-07-19 10:30AM	Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Oct-03-19 07:34AM	The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo (Benzinga) +8.25%
Oct-02-19 07:31PM	Organovo Acknowledges Receipt of Proposal (GlobeNewswire) +5.94%
Sep-11-19 01:29PM	How Does Organovo Holdings, Inc. (NASDAQ:ONVO) Affect Your Portfolio Volatility? (Simply Wall St.)
Sep-06-19 09:36AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Organovo Holdings, Inc.- ONVO (GlobeNewswire)
Aug-08-19 08:50PM	Organovo (ONVO) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.93%
Aug-07-19 09:00AM	Organovo to Explore Strategic Alternatives and Implement Restructuring Plan (GlobeNewswire) -26.48%
Aug-01-19 10:32AM	Organovo (ONVO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-18-19 08:05AM	Organovo Announces Release Date for Fiscal First-Quarter 2020 Financial Results (GlobeNewswire)
Jul-09-19 02:59PM	What Kind Of Shareholders Own Organovo Holdings, Inc. (NASDAQ:ONVO)? (Simply Wall St.) +5.15%
Jul-08-19 08:05AM	Organovo Presents Data on Creating Stem Cell-Based Bioprinted Kidney Organoids at the International Society for Stem Cell Research (ISSCR) 2019 Annual Meeting (GlobeNewswire)
Jun-26-19 06:57AM	Investors are still embracing 3-D printing despite some big IPO misfires (MarketWatch)
Jun-25-19 08:37AM	Penny Stocks to Buy Using Technical Analysis for June 2019 (Investopedia) -6.14%
Jun-13-19 08:05AM	Organovo to Present at Raymond James Life Sciences and MedTech Conference (GlobeNewswire)

VivoSim Labs, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company was founded on January 30, 2012 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VIVS

VivoSim Labs Inc

Upgrade your FINVIZ experience